 |
0 Diseases |  |
123 Trials |
|
123 Trials |  |
2738 News |  |
| «12...2021222324252627282930...4142» |
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial completion date: Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole (clinicaltrials.gov) - Jun 4, 2020
P=N/A, N=44, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Trial completion date: Dec 2019 --> Dec 2021
- || Arimidex (anastrozole) / AstraZeneca, Remedica, Faslodex (fulvestrant) / AstraZeneca
Clinical, Journal: Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response. (Pubmed Central) - Jun 4, 2020
Trial completion date: Dec 2019 --> Dec 2021 FDG-PET/CT imaging could become a "surrogate marker" to monitor tumor response, especially as NET is a valuable treatment option in postmenopausal women with ER+/HER2- BC.
- || Arimidex (anastrozole) / AstraZeneca, Remedica
ALTERNATE: Terapia endocrina(TE) neoadj. para ER+ Fulvestant (+/-anastrozole) no mejoro la tasa de sensitividad endocrina(pCR,PEPI0) vs. anastrozole. ⬇️KI67 fue similar en los grupos <2% en TE neoadj progresaron usando strategia de triaje con Ki67 6/x https://t.co/HqjQxMu5UK (Twitter) - Jun 2, 2020
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score (clinicaltrials.gov) - Jun 1, 2020
P2, N=50, Recruiting, Sponsor: Washington University School of Medicine
FDG-PET/CT imaging could become a "surrogate marker" to monitor tumor response, especially as NET is a valuable treatment option in postmenopausal women with ER+/HER2- BC. Trial completion date: Jul 2024 --> Jun 2025 | Trial primary completion date: Jun 2020 --> Jun 2021
- || Arimidex (anastrozole) / AstraZeneca, Remedica, tamoxifen / Generic mfg.
Reading blood work is fine but suggesting an understanding of virology is a disservice to those that are working to solve this. Stick to tamoxifen and arimidex. (Twitter) - May 30, 2020
- ||| Arimidex (anastrozole) / AstraZeneca, Remedica, Faslodex (fulvestrant) / AstraZeneca
ALTERNATE results show no difference for the combination of fulvestrant plus anastrazole versus anastrazole alone. This is reminiscent of the ATAC results where TAM plus Anastrazole was not superior to single agent endocrine therapy. #ASCO2020 #bcsm (Twitter) - May 30, 2020
- |||| Arimidex (anastrozole) / AstraZeneca, Remedica, Faslodex (fulvestrant) / AstraZeneca
Clinical: Dr. Cynthia Ma presents the Alliance ALTERNATE neoadjuvant endocrine trial. Stage 2/3 ER pos pts randomized time fulvestrant +/- anastrazole with estrogen sensitive disease rate endpoint. Separate adjuvant endpoint not presented. #ASCO2020 #bcsm (Twitter) - May 30, 2020
- Primary Hormonal Therapy for Women Diagnosed with Breast Cancer ≥70 () - May 29, 2020 - Abstract #ASBrS2020ASBrS_171;
This may be due to patient selection. Very few patients in this study required surgery for local control while being treated with PET.
- Endocrine Therapy Persistence Among Elderly Breast Cancer Patients: Impact on Survival () - May 29, 2020 - Abstract #ASBrS2020ASBrS_169;
Minimal differences are observed in endocrine therapy persistence among those receiving surgery with ET, compared to those receiving ET alone. This study suggests that the significant survival benefit observed in patients receiving surgery is not associated with differences in ET use, reflecting the importance of surgical intervention for eligible elderly breast cancer patients for improved overall survival.
- How Effective Is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-conserving Surgery (BCS)? () - May 29, 2020 - Abstract #ASBrS2020ASBrS_152;
Although nodal pCR is more frequent than breast pCR, NET is more likely to be successful in de-escalating breast surgery than axillary surgery if rules developed for neoadjuvant chemotherapy (NAC) are applied to N+ patients, and nodal pCR is required to avoid axillary lymph node dissection. However, with a nodal pCR rate of 12%, NET remains an option for downstaging cN+ patients not eligible for NAC.
- |||| Arimidex (anastrozole) / AstraZeneca, Remedica
ALTERNATE trial: neoadj ET for stage II-III ER+ #breastcancer Fulvestant (+/-anastrozole) did not improve endocrine sensitive disease rate(pCR,PEPI0) vs. anastrozole. KI67 suppression was similar in all arms <2% treated with NET progressed due to Ki67% triaging strategy #ASCO20 (Twitter) - May 29, 2020
- ||| Kisqali (ribociclib) / Novartis
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (clinicaltrials.gov) - May 28, 2020
P2, N=327, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
However, with a nodal pCR rate of 12%, NET remains an option for downstaging cN+ patients not eligible for NAC. Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2020 --> Mar 2021
- || amcenestrant (SAR439859) / Sanofi
Trial primary completion date, Monotherapy, Metastases: AMEERA-3: Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (clinicaltrials.gov) - May 27, 2020
P2, N=372, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2020 --> Mar 2021 Trial primary completion date: Nov 2020 --> Mar 2021
- | Ibrance (palbociclib) / Pfizer
Trial primary completion date, Metastases: Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer (clinicaltrials.gov) - May 27, 2020
P2, N=40, Recruiting, Sponsor: Antoinette Tan, MD
Trial primary completion date: Nov 2020 --> Mar 2021 Trial primary completion date: Mar 2020 --> Jan 2022
- | Review, Journal: Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology. (Pubmed Central) - May 25, 2020
Moreover, prospective clinical trials have shown TDM to be feasible for tamoxifen, for which the exposure-efficacy threshold of its active metabolite endoxifen is 5.97 ng/mL. Based on the available data, we therefore conclude that individualized dosing based on drug concentrations is feasible and promising for oral anti-hormonal drugs and should be developed further and implemented into clinical practice.
- | Afinitor (everolimus) / Novartis
Retrospective data, Review, Journal: Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: A network meta-analysis. (Pubmed Central) - May 23, 2020
Based on the available data, we therefore conclude that individualized dosing based on drug concentrations is feasible and promising for oral anti-hormonal drugs and should be developed further and implemented into clinical practice. Ultimately, our study established that letrozole plus zoledronic acid may be an optimal treatment based on its current rank in a neoadjuvant setting for HR+ breast cancer.
- || Decadron (dexamethasone) / Merck (MSD), Arimidex (anastrozole) / AstraZeneca, Remedica
Clinical, Journal: Mammary adipose stromal cells derived from obese women reduce sensitivity to the aromatase inhibitor anastrazole in an organotypic breast model. (Pubmed Central) - May 23, 2020
Finally, tamoxifen was more effective than anastrazole at reducing aromatization-induced ER transactivation and proliferation. These findings suggest that patient-specific responses to hormone therapies can be modeled and studied organotypically in vitro and add to evidence advocating obesity as a parameter to consider when identifying treatments for patients with ER-positive breast cancer.-Morgan, M. M., Arendt, L. M., Alarid, E. T., Beebe, D. J., Johnson, B. P. Mammary adipose stromal cells derived from obese women reduce sensitivity to the aromatase inhibitor anastrazole in an organotypic breast model.
- || Arimidex (anastrozole) / AstraZeneca, Remedica, tamoxifen / Generic mfg., Ilaxten (bilastine) / Otsuka
Clinical, Journal: Estimating the magnitude of clinical benefit of systemic therapy in patients with DCIS or pre-invasive disease of the breast. (Pubmed Central) - May 23, 2020
Our attention is now focused on prognostic and predictive markers to identify patients who can derive the greatest benefits from low dose tamoxifen, such as for instance the expression of 23 genes involved in cell cycle progression (CCP). In conclusion, we endorse an active treatment of DCIS as the standard of care.
- || Herceptin (trastuzumab) / Roche, Xolair (omalizumab) / Roche, Novartis
Clinical, Journal: Is omalizumab safe and effective in oncological patients? (Pubmed Central) - May 19, 2020
However, in the past year, the intensity and frequency of the outbreaks was increased with the development of angioedema until completing 23 consultations through the emergency department being treated in all of the episodes with short cycles of oral corticosteroids. This case reported is particularly complex due to different points that we develop below: (a) oncological patient as special population; (b) differential diagnosis with other forms of urticaria such as vasculitis urticaria, inducible urticaria, and autoimmune progesterone dermatitis; (c) spontaneous chronic urticaria of difficult control at labeled dose of omalizumab; (d) concomitant treatment with another biological drug.
- | Arimidex (anastrozole) / AstraZeneca, Remedica
Journal: Reversible cerebral vasoconstriction syndrome associated with anastrozole: an unusual cause of high impact (Pubmed Central) - May 17, 2020
In this case, RCVS plus SAH is associated with the use of anastrozole. So far there are no reported cases of aromatase inhibitors associated with this pathology and should be reported in the literature for pharmacovigilance.
- [VIRTUAL] Direct-to-consumer PDE-5 inhibitor telemedicine marketing platforms overlook crucial pathology: Quantifying the value added of the urology office consultation (WEWCC: 152A) - May 17, 2020 - Abstract #AUA2020AUA_2902;
These data support ED as a sentinel risk factor for cardiovascular comorbidities, neglected by DTC online platforms. A considerable proportion of young men had risk factors for subfertility, such as varicocele or elevated FSH, also not captured by DTC platforms.
- Arimidex (anastrozole) / AstraZeneca, Remedica
The interaction between SNP genotype and aromatase inhibitor treatment response in early breast cancer (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_2438;
The signals were lost in the GWAS analysis when anastrozole and exemestane were combined. Preclinical laboratory studies revealed novel functions of LY75 and GPR160 in breast cancer.
- | anastrozole / Generic mfg., tamoxifen / Generic mfg., exemestane / Generic mfg.
New trial: NUTRIBREAST: Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast Cancer (clinicaltrials.gov) - May 14, 2020
P, N=300, Recruiting, Sponsor: Instituto Jalisciense de Cancerologia
- ||| xentuzumab (BI-836845) / Boehringer Ingelheim
Enrollment open, Combination therapy, Metastases: This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer (clinicaltrials.gov) - May 14, 2020
P1, N=148, Recruiting, Sponsor: Boehringer Ingelheim
Preclinical laboratory studies revealed novel functions of LY75 and GPR160 in breast cancer. Suspended --> Recruiting
- || Herceptin (trastuzumab) / Roche
Clinical, Journal: Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients. (Pubmed Central) - May 7, 2020
Trajectory modelling provided detailed information about patterns of nonadherence and critical time periods for adherence to endocrine therapy. This information is important for developing targeted interventions to improve adherence.
- || anastrozole / Generic mfg., exemestane / Generic mfg.
Clinical, Journal: Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer. (Pubmed Central) - May 7, 2020
We were unable to identify common or rare variant regions that added value to the findings from our previous GWAS. We did find two haplotypes that were significant after adjusting for our top GWAS SNP but these were considered to be of marginal value.
- || Arimidex (anastrozole) / AstraZeneca, Remedica
Clinical, Journal: Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study. (Pubmed Central) - May 6, 2020
Long term therapy with subcutaneous testosterone, or testosterone combined with anastrozole, did not increase the incidence of IBC. Testosterone should be further investigated for hormone therapy and breast cancer prevention.
- | NN1213 / Novo Nordisk
Phase classification, Trial primary completion date: Endocrine Response in Women With Invasive Lobular Breast Cancer (clinicaltrials.gov) - May 6, 2020
P2, N=150, Recruiting, Sponsor: Priscilla McAuliffe
Testosterone should be further investigated for hormone therapy and breast cancer prevention. Phase classification: P=N/A --> P2 | Trial primary completion date: Dec 2019 --> Dec 2020
- Ibrance (palbociclib) / Pfizer, Arimidex (anastrozole) / AstraZeneca, Remedica, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] A phase II trial of nivolumab + palbociclib + anastrozole in postmenopausal women with ER+/HER2– primary breast cancer: CheckMate 7A8 (ePosters) - May 5, 2020 - Abstract #ESMOBCI2020ESMO_BC_I_504;
P2
Funding: Bristol-Myers Squibb. Clinical trial identification: NCT04075604.
- | Faslodex (fulvestrant) / AstraZeneca
Review, Journal: Fulvestrant for Untreated Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. (Pubmed Central) - May 2, 2020
The economic model was sensitive to changes in overall survival and the Evidence Review Group considered the incremental cost-effectiveness ratio was uncertain and likely to increase once mature results from FALCON become available. The National Institute for Health and Care Excellence Appraisal Committee concluded that fulvestrant could not be recommended for treating locally advanced or metastatic estrogen-receptor-positive breast cancer in postmenopausal women who have not received previous endocrine therapy.
- | letrozole / Generic mfg., anastrozole / Generic mfg.
Enrollment open: Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer (clinicaltrials.gov) - Apr 29, 2020
P2, N=29, Recruiting, Sponsor: Mayo Clinic
The National Institute for Health and Care Excellence Appraisal Committee concluded that fulvestrant could not be recommended for treating locally advanced or metastatic estrogen-receptor-positive breast cancer in postmenopausal women who have not received previous endocrine therapy. Not yet recruiting --> Recruiting
- Arimidex (anastrozole) / AstraZeneca, Remedica, tamoxifen / Generic mfg., capecitabine / Generic mfg.
[VIRTUAL] Pharmacist assistance for patients on oral oncologic therapy: Impact on adherence and costs. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4907;
Pharmaceutical care was responsible for high rates of adherence, despite the high frequency of adverse effects, and also promoted cost savings. Research Funding: None
- irinotecan / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] Pharmacogenetics findings in Brazilian cancer patients. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3080;
Therefore we can evaluate that the allelic frequency variability of the polymorphs observed, despite the great variability, shows most evaluated individuals present some type of genotypic modification, being the majority in only 1 allele. Research Funding: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – CAPES, Oncológica do Brasil Ensino e Pesquisa
- Ibrance (palbociclib) / Pfizer, Arimidex (anastrozole) / AstraZeneca, Remedica, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] A phase II trial of nivolumab (NIVO) + palbociclib (PAL) + anastrozole (ANA) in postmenopausal women and men with estrogen receptor (ER)+/human epidermal growth factor 2 (HER2)- primary breast cancer (BC): CheckMate 7A8. (Poster Board 190) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1827;
P2
The study is currently enrolling. Research Funding: Bristol-Myers Squibb
- Votrient (pazopanib) / Novartis
[VIRTUAL] Pazopanib (PZ) plus endocrine therapy as treatment for hormone resistant advanced breast cancer (ABC). (Poster Board 153) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1792;
These results support clinical efficacy of antiangiogenic TKI in HR+ ABC, and suggest benefit in hormone resistant disease. Expected toxicities resulted in early discontinuation in 28.6%, which limited drug exposure.
- Arimidex (anastrozole) / AstraZeneca, Remedica, tamoxifen / Generic mfg.
[VIRTUAL] Comparison of StemPrintER, a novel biology-based genomic predictor of distant recurrence in breast cancer, with Oncotype DX in the TransATAC cohort. (Poster Board 105) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1747;
In ER+/HER2- TransATAC BC patients, SPRS was highly prognostic for DM and was superior to RS in providing additional prognostic information to conventional clinicopathological parameters. Research Funding: Italian Association for Cancer Research (AIRC), Cancer Research UK (CRUK)
- Ibrance (palbociclib) / Pfizer, letrozole / Generic mfg., Faslodex (fulvestrant) / AstraZeneca
[VIRTUAL] PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_1735;
P2
As both arms demonstrated comparable 4 years-OS, PF is a reasonable alternative to PL in this setting. Research Funding: Pfizer
- [VIRTUAL] Early-stage breast cancer (BC) patients: Factors associated with aromatase inhibitor-induced musculoskeletal symptoms. (Poster Board 17) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1647;
24% of these changed, held or discontinued AI regimen due to severe AIMSS. Higher BMI at diagnosis was associated with a higher risk of AIMSS.
- Arimidex (anastrozole) / AstraZeneca, Remedica, Faslodex (fulvestrant) / AstraZeneca
[VIRTUAL] ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_1620;
P3
RFS data are awaited. Research Funding: U10CA180821, U10CA180882, U24CA196171; Alliance Foundation, NCI Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP), Breast Cancer Research Foundation, Genentech, AstraZeneca, https://acknowledgments.alliancefound.org
- || Kisqali (ribociclib) / Novartis
Trial completion date, Combination therapy, Metastases: Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (clinicaltrials.gov) - Apr 27, 2020
P2, N=315, Recruiting, Sponsor: Novartis Pharmaceuticals
Research Funding: U10CA180821, U10CA180882, U24CA196171; Alliance Foundation, NCI Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP), Breast Cancer Research Foundation, Genentech, AstraZeneca, https://acknowledgments.alliancefound.org Trial completion date: Apr 2022 --> Dec 2023
- | Arimidex (anastrozole) / AstraZeneca, Remedica
Journal: Anastrozole-induced liver injury after a prolonged latency: a very rare complication of a commonly prescribed medication. (Pubmed Central) - Apr 26, 2020
A review of the literature revealed six prior cases of anastrozole-related liver injury. Anastrozole should be considered as a possible culprit in patients who develop an unexplained acute liver injury.
- | anastrozole / Generic mfg.
Enrollment closed: PHANTOM: Pulmonary Hypertension and Anastrozole Trial (clinicaltrials.gov) - Apr 24, 2020
P2, N=84, Active, not recruiting, Sponsor: University of Pennsylvania
Anastrozole should be considered as a possible culprit in patients who develop an unexplained acute liver injury. Recruiting --> Active, not recruiting
- || Avastin (bevacizumab) / Roche, vinorelbine tartrate / Generic mfg.
Clinical, Journal: Long-Term Survival in a Case of Breast Cancer with Brain Metastases and No Other Distant Metastases Treated by Surgical Removal and Gamma Knife Radiosurgery (Pubmed Central) - Apr 23, 2020
MRI showed that the edema due to radiation necrosis reduced and dyslexia symptoms improved. As of now, she has survivedfor 5 years and 6 months after the diagnosis of brain metastases.
- || Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: BOLERO-5: A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor (clinicaltrials.gov) - Apr 21, 2020
P2, N=159, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
As of now, she has survivedfor 5 years and 6 months after the diagnosis of brain metastases. Recruiting --> Active, not recruiting | Trial completion date: Sep 2021 --> Jul 2022 | Trial primary completion date: Dec 2019 --> Sep 2020
- | Verzenio (abemaciclib) / Eli Lilly
Trial initiation date, Trial suspension, Metastases: AMBRE: Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer (clinicaltrials.gov) - Apr 20, 2020
P3, N=378, Suspended, Sponsor: UNICANCER
Recruiting --> Active, not recruiting | Trial completion date: Sep 2021 --> Jul 2022 | Trial primary completion date: Dec 2019 --> Sep 2020 Initiation date: Jan 2020 --> May 2020 | Not yet recruiting --> Suspended
- Arimidex (anastrozole) / AstraZeneca, Remedica
Reversible Cerebral Vasoconstriction Syndrome Associated with Anastrozole: An Unusual Cause of High Impact () - Apr 17, 2020 - Abstract #NDS2020NDS_17;
- Herceptin (trastuzumab) / Roche
[VIRTUAL] Gruppo Italiano Mammella (GIM) 10 – CONSENT: A phase III randomized study comparing concurrent versus sequential administration of adjuvant chemotherapy (CT) and aromatase inhibitors (AIs) in post-menopausal patients (pts) with hormone receptor-positive (HR+) early breast cancer (EBC) (ePosters) - Apr 17, 2020 - Abstract #ESMOBCI2020ESMO_BC_I_402;
P3
This recommendation is based on preclinical and clinical data suggesting a potential negative interaction between tamoxifen and CT when given concomitantly...Pts with HER2+ BC are eligible only if scheduled to receive adjuvant trastuzumab...The choice of CT regimen is at physician discretion; anastrozole, letrozole or exemestane are given for at least 5 years...Funding: Ricerca finalizzata. Clinical trial identification: 2013-001629-23; NCT02918084.
- letrozole / Generic mfg., Arimidex (anastrozole) / AstraZeneca, Remedica
[VIRTUAL] Genetic polymorphisms of ESR1 are associated with hormone resistance to aromatase inhibitors therapy in patients with metastatic luminal breast cancer (MLBC) (ePosters) - Apr 17, 2020 - Abstract #ESMOBCI2020ESMO_BC_I_384;
Further research is required to provide evidence of the ESR1 gene polymorphisms (A-351G, T-397C) as an additional risk factor of early resistance to AI in patients with MLBC.Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- Ibrance (palbociclib) / Pfizer, Arimidex (anastrozole) / AstraZeneca, Remedica, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] A phase II trial of nivolumab + palbociclib + anastrozole in postmenopausal women with ER+/HER2– primary breast cancer: CheckMate 7A8 (ePosters) - Apr 17, 2020 - Abstract #ESMOBCI2020ESMO_BC_I_266;
P2
Funding: Bristol-Myers Squibb. Clinical trial identification: NCT04075604.
- Herceptin (trastuzumab) / Roche
[VIRTUAL] Gruppo Italiano Mammella (GIM) 10 – CONSENT: A phase III randomized study comparing concurrent versus sequential administration of adjuvant chemotherapy (CT) and aromatase inhibitors (AIs) in post-menopausal patients (pts) with hormone receptor-positive (HR+) early breast cancer (EBC) (ePosters) - Apr 17, 2020 - Abstract #ESMOBCI2020ESMO_BC_I_236;
P3
This recommendation is based on preclinical and clinical data suggesting a potential negative interaction between tamoxifen and CT when given concomitantly...Pts with HER2+ BC are eligible only if scheduled to receive adjuvant trastuzumab...The choice of CT regimen is at physician discretion; anastrozole, letrozole or exemestane are given for at least 5 years...Funding: Ricerca finalizzata. Clinical trial identification: 2013-001629-23; NCT02918084.